Imipenem Cilastatin Injection

[11 November 2016]

Products Affected - Description

Primaxin injection, Merck
250 mg/ 250 mg, vial, 25 count (NDC 00006-3514-58) - discontinued

Reason for the Shortage

  • Fresenius Kabi had imipenem and cilastatin sodium injection on shortage due to increased demand.
  • Hospira had imipenem and cilastatin sodium injection on shortage due to manufacturing delays.
  • Merck has discontinued Primaxin ADD-Vantage vials as well as the 250 mg vials. Merck has Primaxin 500 mg vials available.

Available Products

Primaxin injection, Merck
500 mg/500 mg, vial, 25 count (NDC 00006-3516-59)
Imipenem and Cilastatin Sodium injection, Fresenius Kabi
250 mg/250 mg, vial, 10 count (NDC 63323-0349-20)
250 mg/250 mg, vial, 25 count (NDC 63323-0349-25)
500 mg/500 mg, vial, 10 count (NDC 63323-0322-20)
500 mg/500 mg, vial, 25 count (NDC 63323-0322-25)
Imipenem and Cilastatin Sodium injection, Hospira
500 mg/500 mg, vial, 25 count (NDC 00409-3507-01)
250 mg/ 250 mg, vial, 25 count (NDC 00409-3508-01)

Estimated Resupply Dates

All marketed presentations are available.


November 11, August 1, July 27, June 24 and 10, May 4, April 12, February 25 and 3, January 13, 2016; December 17, November 20 and 11, October 27 and 12, September 16, August 21 and 4, July 10, June 11 and 8, May 13, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
ASHP Product Listing